FX-322 (regenerative hair-cell program): Phase 2b failure and program discontinuation
Record details
- Authors: Frequency Therapeutics (company communications)
- Journal / source: Company announcement / trade press (2023)
- Design: Phase 2b randomized placebo-controlled (hearing restoration)
- Sample: 142 (Phase 2b FX-322-208)
- Primary endpoint: Speech perception at day 90 (hearing outcome — NOT a tinnitus endpoint)
- Randomized: Yes · Sham/placebo-controlled: Yes · Independent of the manufacturer: No
What this research found
FAILED: no statistically meaningful difference vs placebo on the primary (speech perception) or any secondary endpoint (Feb 2023). Program discontinued; company pivoted away from hearing.
Relevance to tinnitus is INDIRECT: FX-322 targeted hearing restoration, and no tinnitus outcome measure was found in any FX-322 publication or coverage reviewed (the published Phase 1b reported none) — claims that tinnitus was measured are unable-to-verify. The failure matters to the regenerative-medicine pipeline narrative, not to any tinnitus evidence rating.
Limitations and conflicts of interest
Company topline; full peer-reviewed publication of the Phase 2b not reviewed.
Funding / conflicts: Company-reported.
Primary sources
Used as evidence for
This is an original summary from the Tinnitus Evidence verified database, checked against the primary source — not a reproduction of the publisher's abstract.